At a glance
ClinicalIndex Comparison Record- ✓Current depression
- ✓Insulin resistance
- ✓Age 18–60
- ✓Current physician/psychiatrist care
- ✕Diabetes
- ✕Unstable heart disease
- ✕Uncontrolled hypertension
- ✕Extensive alcohol use
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rosiglitazone Add-On in Treatment of Depressed Patients With Insulin Resistance: a Pilot Study
In Brief
A clinical study evaluating rosiglitazone for Depression and 2 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as \[AKA\] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinking. We, the researchers at Stanford University, are recruiting men and women who have been diagnosed with depression, and are willing to participate in this 3 month study. Participation involves neuropsychological testing, 2 blood draws called an oral glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the medication, rosiglitazone. Participants are allowed to continue on their current psychiatric medication.
Study Details
Timeline
Interventions
Rosiglitazone was administered at two different doses over the 12-week period.